πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

2,153 results for β€œOu” Clear

  1. DOCETAXEL , Ifinatamab Deruxtecan, Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Stage IV Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. DOCETAXEL , PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , CETUXIMAB, Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Recurrent or metastatic squamous cell carcinoma of the head and neck

    phase 2 small molecule active

    1 trial

  3. DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, CISPLATIN, METHOTREXATE, ETOPOSIDE, MEPACT 4 mg powder for concentrate for dispersion for infusion

    Ningbo Cancer Hospital

    Patients ≀50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  4. DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion, Bintrafusp alfa (anti-PD-L1/TGFΞ² Trap)

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

    phase 2 small molecule active

    1 trial

  5. DR-1031

    Teva Pharma GmbH

    Breakthrough Bleeding

    phase 2 small molecule completed

    1 trial

  6. DURVALUMAB, Ceralasertib

    Istituto Gentili S.r.l.

    Stage III NSCLC patients with loco-regional relapse > 12 months from the end of CRT +/- < 3 metastatic lesions after PACIFIC regimen or PACIFIC-like regimens (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab), regardless of PD-L1 status, but without EGFR, HER-2 or MET exon14 skipping mutations, ALK, ROS1, RET or NTRK rearrangements.

    phase 2 small molecule active

    1 trial

  7. DURVALUMAB, PACLITAXEL ALBUMIN-BOUND, Ceralasertib

    Fondazione Telethon ETS

    ADVANCED TRIPLE NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  8. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  9. Decitabine/Tetrahydrouridine A 5/250 mg, Siklos 1 000 mg film-coated tablet., Placebo (NDec)

    NovoThirteen

    Sickle cell disease

    phase 2 small molecule active

    1 trial

  10. Demcizumab

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 2 small molecule completed

    2 trials

  11. Dermatophagoides Farinae Drops Group 1

    The First People's Hospital of Lianyungang

    Atopic Dermatitis

    phase 2 mab completed

    1 trial

  12. Descartes-08

    Cartesian Therapeutics

    Childhood-onset Systemic Lupus Erythematous

    phase 2 small molecule active

    1 trial

  13. Description and Composition of the Placebo β€’ Placebo oil solution matching the Cannabis Extract Avextra 10/10 Solution. β€’ Pharmaceutical form: solution (oil) β€’ Route of administration: oral β€’ Storage: Store tightly closed below 25Β°C and protected from light like the verum form. β€’ Country of origin: Italy., Cannabis Extract Avextra 10/10 Solution

    Fondazione Telethon ETS

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    phase 2 small molecule active

    1 trial

  14. Dexamethasone

    Quince Therapeutics

    Nervous System Disorder

    phase 2 small molecule completed

    1 trial

  15. Docetaxel

    Karyopharm Therapeutics Inc

    Recurrent Squamous Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  16. Domvanalimab

    Arcus Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  17. Dose Escalation Doublet: Combination of NKTR-214 + nivolumab

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule completed

    1 trial

  18. Double Trouble in Recovery

    BRIGHT MINDS BIOSCIENCES INC.

    Dual Diagnosis

    phase 2 other completed

    1 trial

  19. Double-Blind 0.2mg CBP-307

    S.L

    Moderate to Severe Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  20. Double-blind investigational anti-arrhythmic

    Wyeth is now a wholly owned subsidiary of Pfizer

    Arrhythmias

    phase 2 small molecule terminated

    1 trial

  21. Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank

    BRIGHT MINDS BIOSCIENCES INC.

    Previously Treated Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  22. EBV-specific T cells (EBV-CTLs)

    Evidence Based Cataract Study Group

    EBV-induced Lymphomas

    phase 2 mab completed

    1 trial

  23. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  24. ELIGARD 22,5 mg, poudre et solvant pour solution injectable

    The George Institute

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources